129 related articles for article (PubMed ID: 30852481)
21. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
[TBL] [Abstract][Full Text] [Related]
22. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial.
Méndez-Sánchez N; González V; Chávez-Tapia N; Ramos MH; Uribe M
Ann Hepatol; 2004; 3(3):108-12. PubMed ID: 15505596
[TBL] [Abstract][Full Text] [Related]
23. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (9):125-31. PubMed ID: 22629789
[TBL] [Abstract][Full Text] [Related]
24. [CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA].
Barabanchyk OV; Svintsits'kyĭ AS; Kozak NP
Lik Sprava; 2014 Nov; (11):48-53. PubMed ID: 25528832
[TBL] [Abstract][Full Text] [Related]
25. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.
Eriksson LS; Olsson R; Glauman H; Prytz H; Befrits R; Rydén BO; Einarsson K; Lindgren S; Wallerstedt S; Wedén M
Scand J Gastroenterol; 1997 Feb; 32(2):179-86. PubMed ID: 9051880
[TBL] [Abstract][Full Text] [Related]
26. Ursodeoxycholic acid for nonalcoholic steatohepatitis.
Wu SD; Li L; Wang JY
Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1247-53. PubMed ID: 22864259
[TBL] [Abstract][Full Text] [Related]
27. Artemisia capillaris extract protects against bile duct ligation-induced liver fibrosis in rats.
Han JM; Kim HG; Choi MK; Lee JS; Lee JS; Wang JH; Park HJ; Son SW; Hwang SY; Son CG
Exp Toxicol Pathol; 2013 Sep; 65(6):837-44. PubMed ID: 23298556
[TBL] [Abstract][Full Text] [Related]
28. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.
Lindor KD; Dickson ER; Jorgensen RA; Anderson ML; Wiesner RH; Gores GJ; Lange SM; Rossi SS; Hofmann AF; Baldus WP
Hepatology; 1995 Oct; 22(4 Pt 1):1158-62. PubMed ID: 7557866
[TBL] [Abstract][Full Text] [Related]
29. [Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyl-toxic hepatopathy].
Bettini R; Gorini M
Clin Ter; 2002; 153(5):305-7. PubMed ID: 12510413
[TBL] [Abstract][Full Text] [Related]
30. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice.
Treeprasertsuk S; Silachamroon U; Krudsood S; Huntrup A; Suwannakudt P; Vannaphan S; Wilairatana P
J Gastroenterol Hepatol; 2010 Feb; 25(2):362-8. PubMed ID: 19817958
[TBL] [Abstract][Full Text] [Related]
31. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone.
González-Koch A; Brahm J; Antezana C; Smok G; Cumsille MA
J Hepatol; 1997 Jul; 27(1):143-9. PubMed ID: 9252088
[TBL] [Abstract][Full Text] [Related]
32. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients.
van der Feen C; van der Doef HP; van der Ent CK; Houwen RH
J Cyst Fibros; 2016 Nov; 15(6):834-838. PubMed ID: 27481229
[TBL] [Abstract][Full Text] [Related]
33. Improvement of alanine aminotransferase by administration of suplatast tosilate plus ursodeoxycholic acid in patients with resistance to ursodeoxycholic acid monotherapy on hepatitis C virus-related chronic liver disease.
Matsuda Y; Inada M; Maeda H; Matsuyama T
Intern Med; 2002 Oct; 41(10):774-9. PubMed ID: 12412994
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of ursodeoxycholic acid (UDCA) in the treatment of chronic alcoholic hepatitis].
Preobrazhenskiĭ VN; Taianovskiĭ VIu
Klin Med (Mosk); 1998; 76(5):26-8. PubMed ID: 9644931
[TBL] [Abstract][Full Text] [Related]
35. [Mechanism of geniposide in improving free fatty acid metabolism in rats with non-alcoholic fatty liver disease].
Liang HQ; Lin MT; Zhao X; Zhou HH; Wang HG; Li GH; Wang YJ; Zhang LM; Wang YY; Chen SD
Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(3):470-475. PubMed ID: 28868866
[TBL] [Abstract][Full Text] [Related]
36. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis.
Lepage G; Paradis K; Lacaille F; Sénéchal L; Ronco N; Champagne J; Lenaerts C; Roy CC; Rasquin-Weber A
J Pediatr; 1997 Jan; 130(1):52-8. PubMed ID: 9003851
[TBL] [Abstract][Full Text] [Related]
37. [Treating non-alcoholic fatty liver disease patients of Gan stagnation Pi deficiency syndrome by tiaogan lidi recipe: a randomized controlled clinical trial].
Yu Q; Zhang SS; Zhou T; Xiong Y; Zhao LQ; Ding Y
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Apr; 35(4):401-5. PubMed ID: 26043560
[TBL] [Abstract][Full Text] [Related]
38. N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL.
Oliveira CP; Cotrim HP; Stefano JT; Siqueira ACG; Salgado ALA; Parise ER
Arq Gastroenterol; 2019 Aug; 56(2):184-190. PubMed ID: 31460584
[TBL] [Abstract][Full Text] [Related]
39. [Clinical observation on the safety and efficacy of ursodeoxycholic acid and fuzheng huayu capsule in the treatment of primary biliary cirrhosis].
Wu Y; Yao DK; Zhu L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Nov; 32(11):1477-82. PubMed ID: 23359968
[TBL] [Abstract][Full Text] [Related]
40. [Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease].
Rasskazova MA; Vorobyev SV; Butova HN
Ter Arkh; 2023 May; 95(4):316-321. PubMed ID: 38158979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
